Drug Profile

NG 348

Alternative Names: Membrane bound ligand T-SIGn virus; NG-348

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PsiOxus Therapeutics
Developer Akamis Bio; Bristol-Myers Squibb
Class Oncolytic viruses
Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV)
05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
13 May 2021 NG 348 is still in phase-I development in Solid-tumours in United Kingdom (IV) (PsiOxus Therapeutics pipeline, May 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com